inTrODUcTiOn Primitive hematopoietic precursor cells, specifically hematopoietic stem cells (HSCs), are rare event cells in the bone marrow. In normal circumstances, most of these upstream precursors are maintained in the quiescent state with only a small proportion of them entering into cell cycling for self-renewal and/or proliferation (1) . The homeostasis of HSC quiescence, self-renewal, proliferation, and differentiation secures maintaining the appropriate pool of HSCs while giving rise to all types of blood cells in the body. Our recent studies have revealed that primitive hematopoietic precursor cells in the adult bone marrow constitute a key component of the host immune defense system (2) (3) (4) . During bacterial infection, marrow primitive hematopoietic precursor cells activate rapidly. While increasing proliferation to expand their own population in the bone marrow, these cells reprogram their transcriptional polarization toward enhancing commitment to granulocyte lineage (lin) development. Evoking the granulopoietic response to bacterial infection is critically important for boosting granulocyte production in order for reinforcing the phagocytic defense against invading pathogens. Currently, knowledge about cell signaling mechanisms underlying the activation and reprograming of primitive hematopoietic precursor cells in the process of the granulopoietic response to bacterial infection remains scant.
Hedgehog (HH) signaling has been reported to regulate stem cell activity during embryogenesis (5, 6) and in adulthood (7, 8) . In mammals, three HH genes, including Sonic (shh), Indian (ihh), and Desert (dhh) HH, have been identified (9, 10) . These gene products are initially 45-kDa precursor proteins, which are cleaved and then subjected to cholesterol and palmitoyl modification to produce a 19 kDa active N-terminal fragment (11) (12) (13) . Among three HH proteins, Sonic hedgehog (SHH) is the best studied ligand (14) . SHH molecules are expressed on the cell surface as transmembrane proteins (8, (15) (16) (17) . SHH signals can be mediated through cell-to-cell contact between adjacent cells expressing the SHH receptor patched (PTCH) 1 and 2. Alternatively, NH2-terminal cleavage of SHH can generate a soluble SHH ligand to interact with distal cells expressing PTCH receptors. Binding of SHH ligand to PTCH abolishes PTCH-exerted repression of Smoothened (SMO) allowing SMO to become active, which activates SHH target gene transcription through the glioma-associated oncogene (Gli) transcription factor family (15) (16) (17) . In the Gli family, Gli2 exists in both a full-length active form and a truncated repressor form (18, 19) . Activated SMO prevents cell process of full-length Gli2 transcription factor into a truncated repressor, enabling Gli2 nuclear translocation to activate the transcription of target genes, particular Gli1 (19) (20) (21) (22) . Gli1 is a key transcriptional activator for expression of genes for cell proliferation and survival. Gli1 also activates Gli1 and PTCH (1 and 2) gene expression, which serves as positive and negative feedbacks of SHH signaling, respectively (17) (18) (19) (20) (21) (22) (23) . SHH has been reported to promote primitive hematopoietic precursor proliferation and myeloid differentiation in mouse models (8, 24, 25) . At the present time, nevertheless, it remains elusive if SHH-Gli1 signaling participates in the regulation of primitive hematopoietic precursor cell activation and reprograming in host defense against serious bacterial infection.
In this study, we employed both in vivo and in vitro model systems with manipulations of specific genes to determine the alteration of SHH-Gli1 signal system in bone marrow hematopoietic niche environment and in primitive hematopoietic cells. Our focus was on delineating the role of SHH-Gli1 signaling in the regulation of hematopoietic precursor cell activity during the granulopoietic response to systemic bacterial infection.
MaTerials anD MeThODs animals
Male BALB/c mice (6-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA). Male Gli1 null mice (6-8 weeks old, derived from STOCK Gli1tm2Alj/J Gli1lacZ mutant mice with 129S1/SvImJ strain background) were bred at Northeast Ohio Medical University Comparative Medicine Unit. Breeding pairs of Gli1 null (STOCK Gli1tm2Alj/J Gli1lacZ, Stock No. 008211) and the background control (129S1/SvImJ, Stock No. 002448) mouse strains were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All animals were housed in specific pathogen-free facilities with a 12 h light/dark cycle. This study was carried out in accordance with the recommendations of National Institutes of Health guidelines. The protocol was approved by the Institutional Animal Care and Use Committees of Northeast Ohio Medical University and Michigan State University prior to initiation of all experiments.
Bacteremia was induced in mice as described previously with minor modifications (4). Briefly, an intravenous (i.v. through the penile vein) injection of live Escherichia coli (E. coli, strain E11775 from the American Type Culture Collection, Rockville, MD; 5 × 10 7 CFUs in 100 µl of pyrogen-free saline/mouse) was given to mice under anesthesia with inhalation of isoflurane (Henry Schein Animal Health, Dublin, OH, USA). Control mice received i.v. injection of an equal volume of pyrogen-free saline. In a subset of experiments, E. coli (5 × 10 7 CFU in 50 µl pyrogen-free saline/ mouse) or saline was i.v. injected into mice. Bromodeoxyuridine (5-bromo-2′-deoxyuridine or BrdU, BD Biosciences, San Diego, CA, USA; 1 mg in 100 µl of saline/mouse) was i.v. administered at the same time. Animals were sacrificed at scheduled time points as indicated in each figure legend in the Section "Results".
At the time of sacrifice, a heparinized blood sample was obtained by cardiac puncture. White blood cells (WBCs) were quantified under a light microscope with a hemocytometer. Both femurs and tibias were collected. Bone marrow cells (BMCs) were flushed out from these bones with a total volume of 2 ml RPMI-1640 medium (Life Technologies, Grand Island, NY, USA) containing 2% bovine serum albumin (BSA, HyClone Laboratories, Logan, UT) through a 23-gage needle. BMCs were filtered through a 70-μm nylon mesh (Sefar America Inc., Kansas City, MO, USA). Contaminating erythrocytes in BMC samples were lysed with RBC lysis solution (Qiagen Sciences, Germantown, MD). Nucleated BMCs were washed with RPMI-1640 medium containing 2% BSA and then quantified under a light microscope with a hemocytometer. For determination of SHH level in bone marrow elute and nucleated BMC lysate samples, collected femurs, and tibias from each mouse were flushed with a total volume of 0.5 ml of phosphate-buffered saline (PBS, Life Technologies Co, Grand Island, NY, USA) through a 23-gage needle. Bone marrow elute samples were filtered through a 70-μm nylon mesh. After centrifugation at 500 × g for 5 min, bone marrow eluate (supernatant) samples were collected. Contaminating erythrocytes in the remaining BMC samples were lysed with RBC lysis solution as above. After washing twice with PBS, nucleated BMCs were collected. BMC lysate samples were prepared by lysing cells with a lysing buffer (10 mM Tris-HCl buffer containing 1% Triton X-100, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM PMSF, 50 mM sodium fluoride, 5 mg/ml aprotinin, 5 mg/ml pepstatin, and 5 mg/ml leupeptin, pH 7.6). After centrifugation at 10,000 × g for 10 min at 4°C, the supernatant of BMC lysate sample was collected. Bone marrow eluate and cell lysate samples were stored at −80°C till determination of SHH level.
Preparation of Bacteria
For each experiment, a frozen stock culture of E. coli was added to tryptic soy broth and incubated for 18 h at 37°C in an orbital shaker. Bacteria were collected and washed twice with PBS. Suspension of bacteria in saline at appropriate concentrations was prepared based on its optical density at 600 nm. Actual numbers of viable bacteria were verified by standard plate counts of the bacterial suspensions on MacConkey agar plates following overnight incubation at 37°C. 
culture of Primary Mouse BMcs

Determination of shh level with elisa
Sonic hedgehog level in bone marrow elute and cell lysate samples was determined with enzyme-linked immunosorbent assay (ELISA) using the Mouse Shh-N ELISA Kit (Abcam, Cambridge, MA, USA) and the protocol provided by the manufacturer.
Determination of Protein content with Bca Protein assay
Protein content in biological samples was determined using the BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA) with the protocol provided by the manufacturer.
Flourochrome conjugation of antibody
Flourochrome labeling of anti-human/mouse Gli1 antibody (Clone #388516, R&D Systems, Minneapolis, MN, USA) and the matched isotype control antibody (Clone # 54447, R&D Systems) was performed using DyLight 405 Microscale Antibody Labeling Kit (Thermo Fisher Scientific) with the protocol provided by the manufacturer.
Flow cytometric analysis and cell sorting
Cell phenotype, cell membrane expression of SHH, and intracellular expression of specificity protein 1 (SP1) as well as Gli1 was determined with flow cytometry as previously described (2) (3) (4) . Briefly, nucleated BMCs or WBCs suspended in RPMI-1640 containing 2% BSA (1 × 10 6 cells in 100 µl medium) were added with a mixed panel of biotinylated anti-mouse lin markers [10 µg/ml of each antibody against CD3e (clone 145-2C11), CD45R/B220 (clone RA3-6B2), CD11b (Mac-1, clone M1/70), TER-119 (clone TER-119)] with or without granulocyte differentiation antigen-1 (Gr-1 or Ly-6G/Ly-6C, clone RB6-8C5), or isotype control antibodies (clones A19-3, R35-95, A95-1) (BD Biosciences). Following incubation for 20 min at 4°C, flourochrome-conjugated streptavidin, anti-mouse stem cell growth factor receptor (c-kit or CD117, clone 2B8) and anti-mouse stem cell antigen-1 (antiSca-1, Ly-6A/E, clone D7) without or with anti-Gr1 (Ly-6G, clone 1A8), or the matched isotype control antibodies (BD Biosciences) were added into the incubation system at the final concentration of 10 µg/ml for each agent. Samples were further incubated in the dark for 20 min at 4°C. Antibody-stained cells were then washed with cold PBS containing 2% BSA. For measuring cell BrdU incorporation, cells were further processed using a BD BrdU Flow Kit (BD Biosciences) with the procedure provided by the manufacturer. For measuring cell expression of SHH and SP1, cells were further processed to make both cell membrane and nuclear membrane permeable for antibody using the procedure (without the step of DNA digestion with DNase) provided by BD BrdU Flow Kit (BD Biosciences). Permeablized cells were incubated with 10 µg/ml of anti-human/mouse SHH (Clone E1, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-human/ mouse SP1 antibody (Clone E3, Santa Cruz Biotechnology, Inc.), respectively, in the dark for 20 min at room temperature. Each cell sample was then added with 10 µg/ml of the corresponding flourochrome-conjugated second antibody [polyclonal goat antimouse IgG (H + L), Life Technologies, Eugene, OR, USA and anti-mouse IgG2a, clone R-1915, BD Biosciences]. The cells were further incubated in the dark for 20 min at room temperature. The background staining control samples were incubated with the respective flourochrome-conjugated second antibody only. For determining cell expression of Gli1, permeablized cells were incubated with 10 µg/ml of flourochrome-conjugated antihuman/mouse Gli1 antibody (Clone #388516, R&D Systems) and the isotype control antibody (Clone # 54447, R&D Systems), respectively, in the dark for 20 min at room temperature. At the end of the staining procedure, cells were washed with the washing buffer provided with the BD BrdU Flow Kit (BD Biosciences) and then suspended in 0.5 ml of PBS containing 1% paraformaldehyde. Analysis of cell phenotypes, BrdU incorporation, expression of SHH, SP1, and Gli1 was performed on a FACSAria Fusion flow cytometer with FACSDiva software (Becton Dickinson, San Jose, CA, USA). Cell populations of interest were gated based on their marker or marker combinations. Depending on the cell types being analyzed, the number of cells acquired in each sample was in the range of 5,000-300,000. In a subset of experiments, gated bone marrow lin − c-kit + cells were sorted with FACSAria Fusion flow cytometer (Becton Dickinson).
granulocyte-Macrophage colony-Forming Unit (cFU-gM) assays
Granulocyte-macrophage colony-forming unit assays of freshly sorted bone marrow lin − c-kit + cells were performed by culturing the cells in Methocult GF M3534 medium (StemCell Technologies, Vancouver, BC, Canada) in the absence and presence of recombinant murine SHH (200 ng/ml, eBioscience/ Thermo Fisher Scientific). One milliliter of Methocult GF M3534 medium containing 100 cells was plated to a 35 mm NunclonTM dish (Nunc, Rodkilde, Denmark). The cultures were conducted for seven days at 37°C in an atmosphere of 5% CO2. Colonies containing 50 or more cells were then enumerated.
Western Blot analysis
Western blot analysis of phosphorylated extracellular signalregulated kinase 1/2 (phospho-ERK1/2) and total ERK1/2 protein expression by cells was performed using the protocol reported previously (4, 26, 27) with minor modifications. Protein was extracted from nucleated BMCs with the lysis buffer described above. Protein concentration was determined using BCA protein assay kit (Thermo Fisher Scientific). Thirty micrograms of protein sample were resolved using the 12% SDS-PAGE ready gel (Bio-Rad Laboratories, Hercules, CA, USA) and transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories). The membrane was blocked with 5% milk in tris-buffered saline (BioRad Laboratories) containing 0.1% Tween 20 (Sigma-Aldrich Co.) (TBST buffer) and hybridized sequentially with the primary antibody against phospho-ERK1/2 (anti-mouse phospho-p44/42 MAPK Thr202/Tyr204) and the corresponding HRP-conjugated secondary antibody (Cell Signaling Technology). Determination of the bound antibody was conducted using Amersham ECL Prime Western blotting Detection System (GE Healthcare, Piscataway, NJ) and imaged using Amersham Imager 600 (GE Healthcare Biosciences AB, Uppsala, Sweden). The membrane was stripped with Re-Blot Plus Mild Antibody Stripping Solution (EMD Millipore Cop., Billerica, MA, USA) and then re-probed sequentially with rabbit anti-mouse total ERK1/2 or anti-β-actin antibody (Cell Signaling Technology) and the corresponding HRP-conjugated goat anti-rabbit IgG to determine total ERK1/2 or anti-β-actin content, respectively. Semi-quantification was performed using the ImageJ software. Data are presented as the normalized intensity ratio of the detected protein band versus the loading reference (total ERK1/2 or β-actin) band in the same sample.
real-time rT-Pcr Determination
Total RNA samples were prepared from nucleated BMCs and sorted marrow lin − c-kit + cells with TRIzol reagent (Thermo Fisher Scientific) and RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA) using procedures provided by the manufacturers. Real-time RT-PCR analysis of mRNA expression by cells was performed as reported previously (28) . Each RNA sample was subjected to 2-step real-time RT-PCR using iScriptTM Reverse Transcription Supermix kit and SsoFastTM EvaGreen ® Supermix kit (Bio-Rad Laboratories), respectively, on the CFX96TM RealTime System (Bio-Rad Laboratories). The amplification primer pairs were as follows: SHH Forward 5′-TCCAAAGCTCACATCCACTG Reverse 5′-CGTAAGTCCTTCACCAGCTTG Gli1 Forward 5′-TTGTGGGAGGGAAGAAACCG Reverse 5′-AGCCAGATCCATATGCTGCC 18SrRNA Forward 5′-ATTCGAACGTCTGCCCTATAA Reverse 5′-GTCACCCGTGGTCACCATG These sets of primers were designed using Primer Express software (Life Technologies Co.). The expression of SHH and Gli1mRNA was determined by normalizing the cycle threshold number of their individual mRNA with that of 18S rRNA in each sample. Changes in specific gene mRNA expression by cells from groups with different treatments are expressed as fold alterations over the baseline expression by cells from the corresponding control group. 
statistical analysis
Data are presented as mean ± SEM. The sample size is indicated in each figure legend. Statistical analysis was conducted using Student's t-test for comparison between two groups and one-way ANOVA followed by Student-Newman-Keuls test for comparison among multiple groups. Difference with statistical significance is accepted at p < 0.05.
resUlTs
Upregulation of shh expression by BMcs in response to Bacteremia
Flow cytometric analysis showed that cells in marrow lin + and lin − c-kit + subpopulations significantly increased their expression of SHH 24 and 48 h following i.v. challenge with E. coli (Figure 1) . Marrow lin − cells also exhibited a significant increase in SHH expression 48 h following initiation of bacteremia. This increase in cell expression of SHH in response to systemic bacterial infection was validated by ELISA analysis (Figure 2) . In association with the increase in SHH protein expression, SHH mRNA expression by BMCs was markedly upregulated 12 and 24 h following bacteremia (Figure 3A) , indicating that the regulation at the transcriptional level was involved in the increase in SHH ligand expression by marrow cells in response to E. coli bacteremia. In contrast to the increase in cell-associated SHH level, the level of soluble SHH in bone marrow elute samples was markedly reduced at both 24 and 48 h post i.v. E. coli challenge (Figure 2) , suggesting that either the release of SHH ligand by BMCs was reduced or cell binding of soluble SHH ligand in the hematopoietic niche environment was enhanced or possibly both following the systemic bacterial infection.
activation of erK1/2-sP1 signaling in Mediating Upregulation of shh expression
Analysis of murine shh promoter sequence using the AliBaba2.1 database predicted 14 Sp1 transcription factor binding sites with the identity of sequence greater than 80%. Toll-like receptor 4 (TLR4)-ERK1/2 signaling promotes SP1 expression (29, 30) . We, therefore, determined if ERK-SP1 signaling was involved in the regulation of SHH expression during the host response to bacteremia. As shown in Figure 3B , phospho-ERK1/2 level in BMCs was markedly increased at the early stage (8 h (Figures 3C,D) . In the in vitro culture system, stimulation with LPS caused a significant increase in SHH expression by cultured BMCs (Figure 3E ). This LPS-stimulated increase in SHH expression was abolished by specific MEK1/2 inhibitor PD98059. Reporter gene analysis demonstrated that SP1 markedly activated murine SHH promoter-driven luciferase expression or activity in HEK 293T cells (Figure 3F ).
Baseline gli1 expression by BMc subpopulations
Activation of Gli1 expression by target cells responding to the SHH ligand stimulation is a key step in the SHH signal pathway, (Figure 5) . Mean channel fluorescent intensity (MCF, reflecting the level of specific antigen in the gated cell population) of Gli1 was significantly elevated in LKS and lin + cell subpopulations 24 h following bacteremia (Figure 7) . Real-time RT-PCR determination showed that Gli1 mRNA expression was significantly upregulated in lin − c-kit + cells 24 h following bacteremia ( Figure 8A) . By 48 h of bacteremia, the percentage of Gli1 
shh-gli1 signaling in activation of Primitive hematopoietic Precursor cells
To determine the role of SHH-Gli1 signaling in the activation and reprograming of primitive hematopoietic precursor cells during the granulopoietic response to systemic bacterial infection, we conducted in vivo cell BrdU incorporation and in vitro CFU-GM forming activity experiments. As shown in Figure 8B , the percentage of BrdU 
Gli1
+ cells in LKS cell subpopulation was significantly increased 24 h following bacteremia. The interesting observation was that the increase in BrdU incorporation into LKS cells following bacteremia was essentially in those cells expressing Gli1 (Figure 8C ). Gli1 − LKS did not show any increase in BrdU incorporation. These data suggest that upregulation of Gli1 expression may play a critical role in LKS activation of proliferation during the host response to bacteremia. In vitro culture of sorted marrow lin (Figure 8D) , indicating the enhancement of these hematopoietic precursor cell commitment toward myeloid differentiation and granulocyte lin development in response to SHH stimulation.
impairment of the granulopoietic response to Bacteremia with gli1 gene Deletion
To further verify the role of SHH-Gli1 signaling in the activation of primitive hematopoietic precursor cells during the granulopoietic response to serious bacterial infection, we employed an in vivo model of mice with Gli1 deletion. As shown in Figure 9A , the activity of BrdU incorporation into LKS cells was significantly increased in wild-type mice 24 h following bacteremia. Gli1 deletion did not affect the baseline activity of BrdU incorporation into LKS cells. However, bacteremiainduced activation of BrdU incorporation into LKS cells was significantly attenuated in mice with Gli1 deletion. The activity of BrdU incorporation into marrow lin − cells was also tended to increase (though did not reach the static significance) in response to bacteremia in wild-type mice ( Figure 9B ). This tendency was not seen in mice with Gli1 deletion. Furthermore, the number of granulocytes in the systemic circulation was significantly increased following bacteremia in wild-type mice ( Figure 9C) . Gli1 gene deletion inhibited the increase in granulocytes in the blood stream following systemic E. coli infection.
DiscUssiOn
Activation of the SHH-Gli1 signal transduction pathway initiates at the engagement of SHH ligand to its receptors (PTCH 1 and 2) on the surface of cells (31) . Our current study revealed that E. coli bacteremia significantly upregulated SHH expression by bone marrow hematopoietic cells. Twenty-four hours post intravenous challenge with E. coli, SHH protein expression by arrow lin + and lin-c-kit + cells was significantly upregulated. Furthermore, marrow lin + , lin − , and lin-c-kit + cells all exhibited a significant increase in SHH expression at 48 h of E. coli bacteremia. This increase in SHH expression by marrow hematopoietic cells may support the activation of SHH signaling in the SHH responding cells. Since lin + cells constitute the major hematopoietic cell population in the bone marrow. They apparently serve as the predominant resource for producing SHH ligand in the bone marrow. An interesting observation was that in contrast to the significant increase in the level of cell-associated SHH, the soluble SHH level in the bone marrow reduced markedly following E. coli bacteremia. Therefore, the potential for soluble SHH ligand to activate the SHH signal pathway in distant cells seems to be restricted in this circumstance. Rather, the direct contact between adjacent cells expressing SHH ligand and the correspondent receptors, respectively, is likely critical for effective activation of SHH signaling in the SHH responding cells following systemic bacterial infection. Studies have shown that primitive hematopoietic precursor cells, such as HSCs and upstream progenitors, preferentially lodge in their specific niche compartment relatively separating from sites for storing more mature cells in the bone marrow (32) . Even within the HSC population, those maintaining the status of dormancy are believed to reside in the unique niche structures differing from places housing their counterparts undergoing proliferation in the bone marrow (33) . Take these facts into consideration, it is likely that the enhanced expression of SHH by primitive hematopoietic precursor cells may play an important role in initial activation of SHH signaling in themselves. The upregulated expression of SHH by more mature lin + hematopoietic cells may provide continuing support to activation of SHH signaling in lin-committed precursor cells during the granulopoietic response to systemic E. coli infection. In this study, changes in SHH expression were analyzed primarily in marrow hematopoietic cells. Bone marrow niche environment contains other cell types, including osteoblast cells, stromal cells, and endothelial cells. Further investigation on the alteration of SHH expression by these niche cell types will be helpful for further elucidating their possible involvement in the regulation of SHH signaling in hematopoietic precursor cells during the host response to systemic bacterial infection.
In this study, we observed that SHH mRNA expression by nucleated BMCs was significantly upregulated during the early stage of E. coli bacteremia, indicating the involvement of transcriptional regulation in the enhancement of SHH expression. To delineate the underlying signaling mechanism, we analyzed murine shh promoter sequence using the AliBaba2.1 database. Fourteen SP1 transcription factor binding sites with the identity of sequence greater than 80% were detected. Previous studies have shown that hematopoietic cells including HSCs express full profiles of TLRs (34) . Ligand (such as LPS) binding to TLR4 activates the Ras-c-Raf-mitogen-activated protein kinase ERK kinase 1/2 (MEK1/2) system which in turn activates the ERK1/2 signaling component (35, 36) . Phosphorylation of ERK1/2 promotes its nuclear translocation to activate SP1 expression (29, 30 ). In the current study, we observed that the level of phospho-ERK1/2 in BMCs was markedly increased at 8 h of bacteremia. SP1 expression in marrow lin
, and LKS cells was significantly increased 18 h following E. coli infection. Inhibition of ERK1/2 activation with specific MEK1/2 inhibitor PD98059 abolished LPS-stimulated increase in SHH expression by cultured BMCs. Furthermore, reporter gene analysis demonstrated that SP1 markedly activated murine SHH promoter. These results demonstrate that the TLR4-ERK1/2-SP1 signal pathway plays a key role in the regulation of SHH expression by hematopoietic cells in the bone marrow during the host response to bacteremia.
Gli1 is a key transcription factor in the SHH signal pathway, activation of which promotes expression of downstream gene products for programming cell fate and modulating cell activities (17) (18) (19) (20) (21) (22) (23) − cells leads to phenotypic conversion of LKS − cells to LKS cells, which play an important role in the rapid expansion of LKS cell pool in the bone marrow during the host response to serious bacterial infection (2, 3, 37) . It is apparent that the phenotypic conversion of Gli1 + LKS − cells may also contribute to the marked increase in the number of Gli1 + LKS cells in BMCs following bacteremia in our current study. Transcriptional activation is involved in the increase in Gli1 expression by hematopoietic precursor cells in response to E. coli infection. In our current study, Gli1 mRNA expression was significantly upregulated in lin − c-kit + cells at 24 h following bacteremia. The enhancement of Gli1 expression was also detected in marrow lin + cells during systemic E. coli infection in this study. This increase in Gli1 expression in marrow lin + cells appears to imply that the activation of the SHH signaling may also participate in the regulation of functional activities in lincommitted hematopoietic progenitors during the granulopoietic response to the systemic bacterial infection.
The HH signal pathway is a developmentally conserved regulator for stem cell activities. Studies have shown that HH signaling is involved in the regulation of adult HSC function. Neutralization of HH ligands with specific antibodies inhibits cytokine-induced proliferation of primitive human hematopoietic cells (8) . Conversely, SHH treatment induces the expansion of pluripotent human hematopoietic repopulating cells in the recipient immunodeficient mice. Downstream activation of the HH signal pathway induces expansion of primitive bone marrow hematopoietic cells under homeostatic conditions and during acute regenerative response to 5-fluorouracil-induced ablation of actively cycling cells in the hematopoietic system (7). Deletion of Gli1 in mice causes accumulation of more quiescent HSCs as well as decrease in myeloid development (25) . In the current study, we examined the role of SHH-Gli1 signaling in the activation of primitive hematopoietic precursor cells during the granulopoietic response to system bacterial infection. The results showed that the increase in proliferative activity (as reflected by cell BrdU incorporation) in LKS cells following bacteremia was essentially in those cells expressing Gli1. By contrast, Gli1 − LKS did not exhibit any activation of proliferation. Further more, in vitro stimulation with recombinant murine SHH ligand significantly increased CFU-GM forming activity of sorted lin − c-kit + cells. These data indicate that the SHH-Gli1 signal pathway participates in mediating primitive hematopoietic precursor cell activation and reprograming for enhancing their commitment toward granulocyte lin development.
Employing an in vivo murine model with Gli1 deletion, we further verified the role of SHH-Gli1 signaling in mediating primitive hematopoietic precursor cell activation during the granulopoietic response to systemic E. coli infection. Our data showed that bacteremia-induced activation of proliferation in primitive hematopoietic precursor cells was significantly attenuated in mice with Gli1 deletion. Accompanied with the inhibition of primitive hematopoietic precursor cell activation, the increase in the number of granulocytes in the systemic circulation during the host response to E. coli bacteremia was also inhibited in mice with Gli1 gene deletion. Our results from the current investigation demonstrate that activation of SHH-Gli1 signaling plays a pivotal role in mediating primitive hematopoietic precursor cell activation during the granulopoietic response to serious bacterial infection.
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